Wholesale Pharmacy Business Plan Template

Capital stack: how a wholesale pharmacy actually gets funded

Wholesale pharmacy is not a logistics business pretending to be regulated. It is a regulated supply-chain business pretending to be logistics. Every credible plan in this niche is built around three numbers a credit committee will ask for inside the first thirty seconds of the meeting: total capex, the inventory float, and the days of working-capital gap between paying a manufacturer and collecting from a chain pharmacy or hospital group purchasing organisation. Founders who walk in without those three numbers walk out without a term sheet.

In the United States the canonical stack for a new operator under NAICS 424210 (Drugs and Druggists' Sundries Merchant Wholesalers) is a combination of an SBA 7(a) term loan and a senior asset-based revolver. SBA 7(a) typically funds the warehouse fit-out, the DEA Schedule II vault, the WMS plus EPCIS serialisation platform and the bond stack — tickets in our experience cluster between $350,000 and $2,000,000 with 10-year amortisation on equipment, and lenders such as Live Oak Bank, Newtek and Byline Bank actively underwrite this NAICS code. SBA 7(a) advances up to 90 per cent of project costs, leaving the operator with 10 to 20 per cent equity to seed, per Financial Models Lab, 2025.

The revolver is the half nobody outside the industry talks about. Manufacturer terms on prescription product run net-30 to net-60 (Pfizer, AbbVie, Teva, Sandoz), while customer DSO lands at 28 to 45 days for chain pharmacies, 35 to 55 days for hospital systems, and 18 to 28 days only when you discount for early settlement. A regional secondary distributor turning $14 to $25 million annually carries $2 to $5 million of inventory and $1.5 to $3 million of receivables on any given day. That float must be financed. Lenders like Wells Fargo Healthcare Finance, CIT Healthcare, MidCap Financial and Eastern Bank advance 80 to 85 per cent against eligible Rx receivables and 50 to 65 per cent against inventory at roughly prime plus 2.0 to 3.5 as of April 2026.

In the United Kingdom the equivalent ladder is a commercial property mortgage or asset-finance facility for warehouse and cold-chain capex, layered with a British Business Bank Growth Guarantee Scheme (GGS) facility for working-capital and growth tranches up to £2 million (70 per cent government guarantee), plus an invoice-finance line from Aldermore, Bibby or Time Finance advancing 80 to 90 per cent against the sales ledger. The Start Up Loans scheme caps at £25,000 and is rarely material at this scale, although it can pay for the GDP Responsible Person retainer in the first six months.

The signal investors actually look for. A wholesale pharmacy plan will be rejected for two reasons before any other: an inventory model that ignores DSCSA Authorised Distributor of Record (ADR) economics, and a financial model that under-sizes the working-capital ask. We see roughly seven in ten first-draft plans get returned by SBA underwriters with the same comment — "borrowing base ineligibility for non-ADR purchases." The plan template here is structured to pre-empt that exact rejection.

Sector size, the Big-3 ceiling and where new entrants win

Pharmaceutical wholesale and distribution is a $917.65 billion global market in 2025, per Cognitive Market Research, 2025, with North America accounting for 33.36 per cent of that pool and the United States alone representing approximately 25.41 per cent. Technavio, 2025 projects the global market will grow by USD 976.2 billion between 2024 and 2029, a compound rate near 9.7 per cent — growth driven by specialty biologics, an ageing demographic in the US and EU, GLP-1 anti-obesity volumes, and the steady migration of complex therapies out of hospital and into community oncology and infusion clinics.

The number that matters more for a new operator is the concentration figure. Cencora (formerly AmerisourceBergen), Cardinal Health and McKesson together hold roughly 95 per cent of US drug distribution revenue, per IntuitionLabs analysis, 2025. McKesson alone reported approximately $238 billion in fiscal 2021 revenue; Cencora reported approximately $214 billion in 2021 before the rebrand; Cardinal Health rounds out the trio. Practically every chain pharmacy, hospital and clinic in America runs primary supply through one of those three. A new entrant trying to compete on full-line primary distribution against this trio will lose on price, on data, on integration. Full stop.

The new wholesaler wins on something the Big 3 are structurally bad at. Three real plays sit in the white space:

• Specialty and biologics secondary — cold-chain biologics for community oncology, rare-disease and infusion clinics. Smaller order sizes, higher service intensity, gross margins of 6 to 14 per cent on $4,000-per-vial therapies. Comparables: FFF Enterprises (Temecula CA, plasma and biologics), Anda Inc. (Teva subsidiary, generic-focused).
• Niche generic or veterinary distribution — serving independent pharmacies and 340B clinics that the Big 3 will not service below a $4,000 minimum. Comparables: Morris & Dickson Co. (Shreveport LA), Kinray (now Cardinal subsidiary, Queens NY).
• Compounding raw-material and OTC channel — lower regulatory burden, fragmented buyer base, longer payment terms but better gross.

The United Kingdom is a more concentrated and explicitly regulated market. The MHRA register lists in the order of 1,800 active WDA(H) holders. AAH Pharmaceuticals (Coventry, the UK's largest full-line wholesaler), Alliance Healthcare UK (Chessington), Phoenix Healthcare Distribution (Runcorn) and Mawdsleys (Doncaster) sit at the top tier. Independent and specialty entrants (parallel-trade-focused, hospital-tender, niche dermatology or unlicensed-special) operate below that. The UK Department of Health and Social Care reports a community pharmacy retail market of approximately £13 billion in NHS-funded volume; wholesale margins are sub-3 per cent on branded prescription, materially higher on parallel imports and unlicensed specials.

Real launch costs: warehouse, vault, EPCIS

A credible wholesale pharmacy launch in the United States ranges from $350,000 to $2.5 million. In the United Kingdom the equivalent range is £280,000 to £1.8 million. The reason for the spread is structural: a single-state, generic-and-OTC-only secondary in a 4,000 square-foot facility with no Schedule II handling sits at the floor; a specialty cold-chain operation with a CII vault and 30-state licensing sits near the ceiling. The plan must pick a configuration and defend it — a credit committee will not finance a midpoint.

Itemised capex and opening costs — United States

• Warehouse lease deposit + 3 months prepaid rent for a GDP-grade unit (4,000–14,000 sq ft, $9–$22/sq ft/yr depending on metro), plus validated HVAC keeping 15–25°C and CCTV with 90-day retention: $45,000–$240,000
• Validated 2–8°C cold chain (qualified pharma fridges, monitored Thermo King or Carrier Transicold reefer trucks if delivering, calibrated Vaisala or Berlinger temperature mapping): $60,000–$220,000
• DEA Schedule II controlled-substance vault built to 21 CFR 1301.72(a) specs (steel-lined, alarmed, biometric access, masonry walls): $25,000–$95,000 (skip if not handling CII)
• WMS plus DSCSA EPCIS serialisation platform — TraceLink, rfxcel (now Antares Vision), SAP ATTP, or Movilitas: $45,000–$180,000 year-one implementation, $1,400–$8,500/month thereafter
• State Wholesale Drug Distributor licences across operating footprint at $200–$1,200 per state, plus surety bonds at $5,000–$100,000 per state (collateral or annual premium of $250–$2,500 each): $25,000–$120,000 stack
• NABP Drug Distributor Accreditation (formerly VAWD), initial fee in the order of $5,000 plus the 2024 Supply Chain Inspection $900 increase: $6,000–$15,000 first cycle, plus consultancy
• DEA Form 225 distributor registration (~$3,047 for the 3-year cycle) plus vault inspection prep: $4,000–$12,000
• Opening prescription inventory (manufacturer net-30 to net-60 credit covers 60–80 per cent of this, but cash float is required): $120,000–$1,500,000 net of AP
• Insurance stack (general liability, product liability, professional indemnity for the pharmacist-in-charge, cargo, cyber, employer's): $22,000–$70,000/yr
• Working-capital buffer sized for the 30–55 day DSO gap on customer payments: $150,000–$400,000

Itemised capex and opening costs — United Kingdom

• Warehouse lease deposit + first quarter rent on an industrial unit (£9–£16/sq ft/yr in the Midlands or North; £18–£30 inside the M25): £30,000–£160,000
• GDP-grade fit-out, validated HVAC, racking, MHE, security: £45,000–£180,000
• 2–8°C cold chain (calibrated qualified fridges, mapped reefer): £35,000–£120,000
• WMS + FMD/UK NMVS decommissioning gateway connection (SecurMed UK, Movilitas, rfxcel): £25,000–£110,000 year-one
• MHRA WDA(H) application fee (£1,732 baseline) plus annual fees, plus pre-inspection consultancy: £8,000–£25,000
• Home Office Controlled Drugs Licence (Schedule 2 to 5) — £3,655 application plus cabinet certification: £5,000–£12,000
• GDP Responsible Person — in-house RP at £55,000–£90,000 salary, or external retainer with a firm such as Pharmacy Consulting or ProPharma at £18,000–£30,000/yr
• Opening prescription stock: £90,000–£900,000 net of supplier credit
• Insurance stack (public liability, product liability, employer's, professional indemnity): £14,000–£45,000/yr
• Working-capital buffer: £100,000–£300,000

The single line item operators most commonly under-budget is the surety-bond stack. State pharmacy boards in the US increasingly require a $100,000 bond per location of operation; if you intend to ship into 30 states, you are quoting at three to thirty bond carriers and posting either annual premium or hard collateral against each. The right answer is usually a single pharmacy-wholesale bond programme through a specialist broker like NFP, Marsh, or Lockton.

Margin stack and a worked $14M secondary unit economics example

The gross-margin distribution in this niche is bimodal. Branded prescription — the long-tail of every Lipitor follow-on, every Eliquis, every Humira biosimilar — transacts at 1.5 to 3.5 per cent gross because the Big 3 set the WAC-plus benchmark and chain pharmacies and PBMs negotiate every basis point. Generic prescription transacts at 8 to 22 per cent gross depending on whether you are an Authorised Distributor of Record buying directly from Sandoz or Teva or whether you are acting as a secondary buying via the open market. OTC, devices and adherence packaging move at 12 to 25 per cent gross. The blend a credible plan models for a generic-weighted secondary lands around 9 to 11 per cent gross; for a specialty cold-chain operator, 14 to 22 per cent gross.

Revenue streams a wholesale pharmacy actually books

• Cost-plus margin on case sales — primary driver, anchored to Wholesale Acquisition Cost (WAC) on brand and to acquisition cost on generic.
• Manufacturer rebates and chargebacks — on contracted GPO and 340B sales, often 1–6 per cent of pass-through revenue, settled monthly via a chargeback file.
• Logistics and prepack fees — unit-dose repackaging, blister packs, kit assembly for clinical trials. 8–18 per cent gross.
• Returns processing fees — the reverse-distribution leg (Inmar, Capital Returns) but increasingly insourced for specialty operators.
• 3PL fees on consigned product — for manufacturers using your warehouse without taking title, typically a per-line storage and handling tariff.

Worked example — regional generic + OTC secondary, Year 3

A secondary wholesaler in a single state turning $14 million in annual revenue at an 11 per cent blended gross books $1.54 million of gross profit. Subtract the realistic operating cost stack for a 6,500 square-foot GDP warehouse:

• Payroll (4 warehouse FTEs at $52K, 1 pharmacist-in-charge at $135K, 1 GM at $115K, 1 finance at $78K, 1 sales at $90K + commission, plus benefits at 22 per cent): $640,000
• WMS + EPCIS subscription, integrations, VAR support: $180,000
• Rent, utilities, validated HVAC service contracts: $110,000
• Insurance stack and surety bond premiums: $75,000
• Outbound freight (FedEx Custom Critical, Quick International, in-house): $90,000
• Interest on a $4 million asset-based revolver at SOFR + 2.75 per cent (~7.05 per cent, ~85 per cent average utilisation): $240,000
• Other operating (legal, NABP fees, state board renewals, software): $95,000

Net contribution: roughly $110,000 in Year 3 on $14 million revenue, or a 0.8 per cent net margin under conservative assumptions; raise the blended gross to 13.5 per cent (specialty mix) or push utilisation of the revolver lower and the same operation prints 2.4 to 4.1 per cent net. Inventory turn of 11.5x and Days Sales Outstanding of 32 drive the working-capital ask. A 1-day improvement in DSO is worth roughly $38,000 in freed cash on this revenue base.

The lesson is that wholesale pharmacy is a balance-sheet business, not an income-statement business. The investor narrative must lead with how you intend to compress DSO and stretch DPO, not with the brand-name therapies you intend to carry.

Investor pitch: a one-paragraph fill-in-the-blanks

Lenders read a hundred pharmacy-wholesale opening paragraphs a year. Almost all of them open with "we are a leading provider of pharmaceutical distribution services". That sentence dies on the first read. Below is the format we use in every Avvale bespoke plan; copy it verbatim and substitute your own variables.

Two things to notice. First, the sentence is structurally an investability test, not a marketing line: every blank is a number or a contract. Second, the moat is named, not implied. "Service" or "relationships" are not a moat in this category — an ADR letter from Sandoz or a 340B contract pharmacy roster is a moat. The plan must show the document.

Federal, MHRA, CDSCO, Health Canada licensing

Wholesale pharmacy is one of the most licence-heavy small-business categories in the world. This is not optional or marketing language; without these certificates you cannot legally hold or move prescription product, and the Big 3 will not transact with you absent every single one.

United States — the federal and state ladder

• State Wholesale Drug Distributor licence — issued by each state Board of Pharmacy under the framework of 21 CFR Part 205. Application $200–$1,200 per state, plus a $5,000–$100,000 surety bond per state. Timeline 8 to 16 weeks per state; nationwide footprint takes 9 to 18 months. California (DCA Board of Pharmacy), Texas (DSHS) and Florida (DDC) have the strictest pre-licensing background investigations.
• NABP Drug Distributor Accreditation (formerly VAWD), per NABP, 2025 — mandated as a substitute for state-level inspection in roughly 30 states, including Indiana, Iowa, Maryland, Michigan, Mississippi, Montana, Nevada, New Mexico, North Dakota, South Dakota, Utah, Wyoming. Initial application around $5,000 with a 2024 Supply Chain Inspection price increase of $900. LighthouseAI, 2025 documents the schedule. Three-year cycle; the application-to-accreditation timeline is 7 to 12 months.
• DEA Form 225 Distributor Registration — required under 21 CFR Part 1301 if you handle any Schedule II to V controlled substances. Three-year registration cycle; current distributor fee approximately $3,047. Vault-build inspection by a DEA Diversion Investigator is required and cannot be skipped — backlog runs 8 to 16 weeks depending on the field office.
• FDA Wholesale Drug Distributor reporting — under the Drug Supply Chain Security Act, all wholesale distributors must report annually. Free of fee but mandatory.
• DSCSA EPCIS interoperable trading-partner compliance — the 27 November 2023 deadline triggered a stabilisation period; FDA, 2024 extended wholesale distributor enforcement to 27 August 2025. From that date you must accept and pass T3 (transaction information, transaction history, transaction statement) data electronically via EPCIS 1.2, with serialisation at the unit level for tracing.

United Kingdom — MHRA and Home Office

• Wholesale Distribution Authorisation, Human use — WDA(H), issued by the MHRA per gov.uk, 2025. Application fee £1,732, plus a 90-working-day standard processing time and a mandatory site inspection. The named Responsible Person (RP) must hold a science or pharmacy degree and demonstrable Good Distribution Practice experience.
• Good Distribution Practice (GDP) compliance — ongoing, demonstrable through SOPs, deviation logs, training records. Inspection failure is the single most common cause of WDA(H) suspension.
• Home Office Controlled Drugs Licence — required for Schedule 2 to 5; application £3,655. Cabinet certification under the Misuse of Drugs (Safe Custody) Regulations 1973 is required.
• UK Falsified Medicines Directive (FMD) / NMVS verification gateway — SecurMed UK connection mandatory for branded prescription decommissioning at point of dispense. Wholesalers verify aggregated codes upstream.

Other jurisdictions a credible plan addresses

• India — Form 20B and 21B: state Drug Licensing Authority issues wholesale licences; pharmacist with a degree plus 1 year of dispensing experience required; minimum 15 sqm with refrigerator and air-conditioning; fees Rs 3,000–6,000.
• Canada — Drug Establishment Licence (DEL): Health Canada issues under the Food and Drugs Act for wholesalers handling Schedule F products; GMP-style annual review, inspection by Health Canada Regulatory Operations and Enforcement Branch.
• European Union (post-Brexit): each member state issues its own national WDA equivalent. Qualified Person and Responsible Person requirements differ across DE, FR, IE, NL. EMVS verification mandatory.
• UAE — Ministry of Health and Prevention (MOHAP): pharmaceutical wholesale licensing under the federal Pharmacy Practice law; DED commercial licence required; foreign ownership rules now allow 100 per cent in many emirates.

State-by-state surety bond and licensing reality

A nationwide footprint is the biggest hidden cost in a wholesale pharmacy business plan. Lenders cap the line at the bond stack, and bond stack scales linearly with state count. Below is the working table our team uses when sizing the licensing tranche of a 50-state plan; numbers are 2026 working figures from broker submissions and state board fee schedules.

• California — state wholesale licence renewal $1,055 every 2 years, $100,000 surety bond per location, mandatory state inspection. Annual bond premium $750–$2,500 per location.
• Texas — DSHS Wholesale Distributor licence $920/yr, $100,000 bond, fingerprint-based criminal history. Strictest non-California pre-licensing review.
• Florida — Department of Business & Professional Regulation, $800 application + permit fee, $100,000 bond, criminal history check by FDLE. 12-week timeline.
• New York — State Board of Pharmacy registration $895 every 3 years, $100,000 bond, additional Article 137 compliance.
• Indiana, Iowa, Michigan, Maryland, Mississippi, Nevada, New Mexico, North Dakota, South Dakota, Utah, Wyoming — accept NABP DDA in lieu of state inspection. Cuts pre-licensing time by 6 to 14 weeks.
• Illinois — IDFPR Wholesale Drug Distributor licence $930 every 2 years, $100,000 bond, plus separate Controlled Substances Distributor licence $200/yr.
• Pennsylvania — State Board of Pharmacy $360 every 2 years, $100,000 bond, criminal history.
• Massachusetts — Department of Public Health Drug Control Program licence $500 every 2 years, $100,000 bond.
• Nevada — Board of Pharmacy wholesale distributor licence $850/yr, $100,000 bond, NABP DDA accepted.

Total bond stack for a true nationwide footprint runs $80,000 to $300,000 in collateral or annual premium. Brokers like NFP, Lockton and Marsh consolidate bond carriers (Liberty Mutual, Hartford, Travelers) into one programme; expect to post 1 to 3 per cent of bond face value annually if your personal credit and the entity balance sheet support it, otherwise full collateral against a credit line.

The strategic insight is sequencing. Start with the home state plus three high-volume neighbours, hit revenue, then add states quarterly as the licensing budget allows. A common mistake is filing 20 state applications simultaneously and burning $40,000 of legal and consultancy time on states that will not contribute to year-one revenue.

Seven expensive mistakes new wholesalers make

Across the bespoke plans Avvale has written for wholesale pharmacy operators, the same seven errors keep surfacing. Each one of these has been the proximate cause of an SBA decline letter or an ABL borrowing-base shortfall on a deal we have been pulled in to rescue.

1. Treating the warehouse as a 3PL while ignoring DSCSA EPCIS. If your IT stack cannot accept and emit T3 data via EPCIS 1.2 from go-live, you cannot legally take ownership of branded prescription product. An ADR contract with Sandoz or Teva will not survive an audit if your tracing breaks. Budget $45K to $180K of year-one platform cost.
2. Modelling primary-wholesaler economics on a secondary-wholesaler capital base. The Big 3 transact at 1.5 per cent gross because they have $30 billion of inventory turn. Your $4 million inventory line cannot run that math. If your plan blends 1.5 per cent gross on $14 million of revenue, your underwriter will catch it before the second page.
3. Buying inventory before the DEA Schedule II vault has passed Diversion inspection. You cannot store CII without it, and the inspection backlog runs 8 to 16 weeks. Receiving CII into an unapproved vault is a federal offence.
4. Sourcing from non-Authorised Distributors of Record (ADRs) and triggering pedigree breaks under DSCSA. Most chain pharmacies will refuse to receive product without verifiable ADR provenance. Secondary buying without an ADR letter is the fastest way to a state board complaint.
5. Hiring a Responsible Person in the UK who lacks GDP audit experience. MHRA inspectors will fail the WDA(H) at site visit. The fastest UK rejection we have seen took five weeks from application to refusal because the named RP had pharmacy retail experience but no GDP.
6. Underestimating the surety-bond stack. 30 states at $100K bond each is $3 million of bond face value. At 2 per cent annual premium that is $60K of recurring cost a founder typically forgets when modelling overhead.
7. Forecasting cash with retail-pharmacy logic. A retail pharmacy collects from PBMs in 14 days. A wholesaler collects from chain customers in 32 to 45 days. Get this wrong and your asset-based revolver covenant trips inside 90 days of opening.

Sample business plan preview

An extract from a real specialty wholesale pharmacy plan written by our team. The tone, specificity and financial voice are what an SBA underwriter or ABL credit committee actually expects.

What is in the template

Every Avvale business plan template is pre-structured for the industry. The wholesale pharmacy edition is built specifically for the questions an SBA underwriter, ABL credit officer, or specialty manufacturer ADR committee will ask before they say yes:

• Executive Summary with the one-paragraph investor pitch fill-in above
• Company Overview covering legal structure, ownership, founder credentials (PharmD, MBA, RPh, channel tenure) and corporate moat statement
• Industry Analysis with Cognitive Market Research, Technavio, IBISWorld and IntuitionLabs citations pre-placed and the Big-3 ceiling addressed
• Customer Analysis with channel tables (chain pharmacy, independent pharmacy, hospital, 340B clinic, long-term care, infusion centre, community oncology)
• Competitor Analysis with named-comparable mapping (Cencora / McKesson / Cardinal at the ceiling, FFF, Anda, Morris & Dickson, AAH, Phoenix as the secondary-band reference set)
• Operations Plan covering warehouse layout, GDP zoning, cold-chain validation, DEA vault spec, WMS plus EPCIS architecture
• Regulatory and Compliance section with state-by-state licensing, NABP DDA, DEA Form 225, DSCSA EPCIS, MHRA WDA(H), Home Office Schedule 2-5, FMD and Health Canada sub-sections
• Marketing and Customer Acquisition Plan with named industry events (NABP Annual Meeting, HDA Distribution Management Conference, ASCP), broker relationships, GPO contracting strategy
• Management Team template with PharmD / MBA / RP credentialing, advisory board, GDP Responsible Person retainer or hire
• Financial Plan optional add-on: 5-year model with explicit cash-conversion cycle worksheet, ABL borrowing-base formula, surety-bond stack scheduling, DSCSA capex amortisation

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) ships a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, scenario toggles for primary versus secondary versus specialty, and a live borrowing-base sheet so you can demonstrate ABL eligibility on demand.

Useful companion pages on Avvale: the free business plan templates hub, the industry-specific template shop, the research and content service, the bespoke plan service, and adjacent BPT guides for a medical supply distributor, a retail pharmacy, or a medical equipment rental operator if you are stress-testing complementary models. Our broader business plan writer service handles the done-for-you tier.

Frequently asked questions